The Safety of Advanced Topical Therapies in Inflammatory Dermatoses

In “The Safety of Advanced Topical Therapies in Inflammatory Dermatoses,” our panel explores the consensus statements evaluating the short- and long-term safety of advanced targeted topical therapies for inflammatory skin diseases. The expert faculty review the growing body of clinical trial evidence supporting several nonsteroidal topical treatments, including roflumilast, tapinarof, ruxolitinib, crisaborole, and delgocitinib, and discuss how these therapies have expanded treatment options across multiple inflammatory dermatoses.

The discussion highlights the safety and tolerability profiles observed in both short-term and long-term studies, including low rates of serious adverse events, treatment discontinuations, and application-site reactions for many of these therapies. Faculty members emphasize the significance of long-term safety data, noting that many of these agents are frequently incorporated into maintenance treatment strategies where ongoing disease control is required. The panel reflects on how the availability of multiple targeted nonsteroidal options represents a major advancement compared with the limited therapeutic landscape that existed only a decade ago.

Beyond reviewing safety data, the expert faculty discuss how these therapies are influencing treatment decisions in clinical practice. Particular attention is given to patient populations that may benefit from earlier incorporation of steroid-sparing approaches, including pediatric patients, individuals receiving corticosteroids from multiple sources, and those with disease involving sensitive skin areas such as the face, neck, genitalia, and intertriginous regions. The panel also explores how efficacy, safety, tolerability, accessibility, and long-term disease control collectively contribute to treatment selection, reinforcing the growing role of advanced topical therapies as foundational tools in the management of inflammatory dermatoses.

Our next episode, “The Evolving Role of Nonsteroidal Topicals in Inflammatory Dermatoses,” features the panelists discussing how advanced nonsteroidal topical therapies can support durable disease control and long-term maintenance in inflammatory dermatoses. The faculty examine the shift from reactive flare management to proactive treatment strategies and explore factors that may limit broader adoption of these therapies in clinical practice.